Skip Navigation


Japanese Journal of Clinical Oncology Advance Access originally published online on April 23, 2007
Japanese Journal of Clinical Oncology 2007 37(3):175-180; doi:10.1093/jjco/hym008
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
37/3/175    most recent
hym008v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Sekine, I.
Right arrow Articles by Tamura, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sekine, I.
Right arrow Articles by Tamura, T.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


© 2007 Foundation for Promotion of Cancer Research

Phase I Study of Cisplatin Analogue Nedaplatin, Paclitaxel, and Thoracic Radiotherapy for Unresectable Stage III Non-Small Cell Lung Cancer

Ikuo Sekine1,, Minako Sumi2, Yoshinori Ito2, Terufumi Kato1, Yasuhito Fujisaka1, Hiroshi Nokihara1, Noboru Yamamoto1, Hideo Kunitoh1, Yuichiro Ohe1 and Tomohide Tamura1

1 Divisions of Internal Medicine and Thoracic Oncology
2 Radiation Oncology, National Cancer Center Hospital, Tokyo, Japan

For reprints and all correspondence: Ikuo Sekine, Division of Internal Medicine and Thoracic Oncology, National Cancer Center Hospital, Tsukiji 5-1-1, Chuo-ku, Tokyo 104-0045, Japan. E-mail: isekine{at}ncc.go.jp

Received September 6, 2006; accepted November 1, 2006

Background: The standard treatment of unresectable stage III non-small cell lung cancer is concurrent chemoradiotherapy in patients in good general condition, but where the optimal chemotherapeutic regimen has not been determined.

Methods: Patients with unresectable stage III non-small cell lung cancer received nedaplatin (80 mg/m2) and paclitaxel on day 1 every 4 weeks for 3–4 cycles and concurrent thoracic radiotherapy (60 Gy/30 fractions for 6 weeks) starting on day 1. The dose of paclitaxel was escalated from 120 mg/m2 in level 1, 135 mg/m2 in level 2 to 150 mg/m2 in level 3.

Results: A total of 18 patients (14 males and 4 females, with a median age of 62.5 years) were evaluated in this study. Full cycles of chemotherapy were administered in 83% of patients in level 1, and in 50% of patients in levels 2 and 3. No more than 50% of patients developed grade 4 neutropenia. Transient grade 3 esophagitis and infection were noted in one patient, and unacceptable pneumonitis was noted in three (17%) patients, two of whom died of the toxicity. Dose-limiting toxicity (DLT), evaluated in 15 patients, noted in one of the six patients in level 1, three of the six patients in level 2 and one of the three patients in level 3. One DLT at level 2 developed later as radiation pneumonitis. Thus, the maximum tolerated dose was determined to be level 1. The overall response rate (95% confidence interval) was 67% (41–87%) with 12 partial responses.

Conclusion: The doses of paclitaxel and nedaplatin could not be escalated as a result of severe pulmonary toxicity.

Key Words: non-small cell lung cancer • chemoradiotherapy • paclitaxel • nedaplatin • pneumonitis


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.